Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Infliximab in Eyes With Penetrating Keratoplasty
NCT05180994Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in Glaucoma, sponsored by Centre hospitalier de l’Université de Montréal. Started May 2022; status: recruiting.
02
Drugs
infliximab
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT05180994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180994.